X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (54) 54
humans (51) 51
oncology (47) 47
cancer (31) 31
female (25) 25
male (25) 25
middle aged (25) 25
aged (21) 21
colorectal cancer (20) 20
adult (19) 19
care and treatment (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
chemotherapy (15) 15
patients (13) 13
analysis (12) 12
colorectal neoplasms - drug therapy (12) 12
mutation (12) 12
research (12) 12
antineoplastic agents - therapeutic use (11) 11
clinical trials (11) 11
disease-free survival (11) 11
medicine & public health (11) 11
metastasis (11) 11
tumors (11) 11
cetuximab (10) 10
health aspects (10) 10
oxaliplatin (10) 10
survival (10) 10
aged, 80 and over (9) 9
biomarkers (9) 9
colorectal neoplasms - pathology (9) 9
therapy (9) 9
animals (8) 8
bevacizumab (8) 8
cancer patients (8) 8
multidisciplinary sciences (8) 8
prognosis (8) 8
treatment outcome (8) 8
1st-line treatment (7) 7
camptothecin - analogs & derivatives (7) 7
cancer research (7) 7
cancer therapies (7) 7
colorectal neoplasms - genetics (7) 7
hematology, oncology and palliative medicine (7) 7
kaplan-meier estimate (7) 7
medicine (7) 7
neoplasm staging (7) 7
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - pharmacology (6) 6
article (6) 6
drug therapy (6) 6
endothelial growth-factor (6) 6
fluorouracil - administration & dosage (6) 6
leucovorin (6) 6
metastatic colorectal-cancer (6) 6
mutations (6) 6
neoplasm metastasis (6) 6
oncology, experimental (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
science (6) 6
survival analysis (6) 6
camptothecin - administration & dosage (5) 5
colorectal carcinoma (5) 5
diagnosis (5) 5
disease progression (5) 5
drug resistance (5) 5
drug resistance, neoplasm (5) 5
esophageal cancer (5) 5
expression (5) 5
fluorouracil (5) 5
genetic aspects (5) 5
genomics (5) 5
high-throughput nucleotide sequencing (5) 5
leucovorin - administration & dosage (5) 5
medical and health sciences (5) 5
medical research (5) 5
medicin och hälsovetenskap (5) 5
mortality (5) 5
pancreatic cancer (5) 5
prostate cancer (5) 5
proteins (5) 5
research article (5) 5
1506 (4) 4
abridged index medicus (4) 4
adenocarcinoma (4) 4
adenocarcinoma - drug therapy (4) 4
aflibercept (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
biological markers (4) 4
biomarkers, tumor - genetics (4) 4
breast-cancer (4) 4
cancer and oncology (4) 4
cancer och onkologi (4) 4
cell lung-cancer (4) 4
chemotherapy, adjuvant (4) 4
clinical medicine (4) 4
clinical trials as topic (4) 4
colonic neoplasms - pathology (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis | Life Sciences | Human health and pathology
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9911, pp. 31 - 39
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e103634
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 2, pp. 320 - 331
Abstract Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan... 
Hematology, Oncology and Palliative Medicine | Subgroup analysis | VEGF Trap | Aflibercept | Metastatic colorectal cancer | Performance status | Bevacizumab | SOLID TUMORS | ONCOLOGY | GROWTH-FACTORS | Leucovorin - administration & dosage | Prospective Studies | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Diarrhea - chemically induced | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Neutropenia - chemically induced | Recombinant Fusion Proteins - administration & dosage | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Receptors, Vascular Endothelial Growth Factor - adverse effects | Antimitotic agents | Care and treatment | Analysis | Colorectal cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 9, pp. 2699 - 2707
Purpose: To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor. Patients and Methods: This was... 
CANCER-CELLS | FREQUENT | ONCOLOGY | FIBROBLAST | SENSITIVITY | MUTATIONS | RECEPTORS | CELL-CARCINOMA
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e80437
This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II... 
MULTIPLE-MYELOMA | TARGET | NK-CELL-FUNCTION | ACTIVATION | CC-5013 | CC-4047 | MULTIDISCIPLINARY SCIENCES | TUMOR-CELLS | CEREBLON | POMALIDOMIDE | INHIBIT | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - genetics | Humans | Proto-Oncogene Proteins - genetics | Thalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Thalidomide - analogs & derivatives | Antibodies, Monoclonal, Humanized - administration & dosage | Colorectal Neoplasms - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Thalidomide - immunology | Mutation | Thalidomide - therapeutic use | Antibodies, Monoclonal, Humanized - immunology | Cetuximab | Cancer patients | Lymphocytes | Oncology, Experimental | Immunotherapy | Colorectal cancer | Clinical trials | Research | Metastasis | Angiogenesis inhibitors | Cancer | CD8 antigen | CD45RA antigen | Colorectal carcinoma | Helper cells | Multiple myeloma | Cytotoxicity | Lymphocytes T | Immunity | Metastases | Ethics | Killer cells | Natural killer cells | Drug dosages | Immune system | Immunological memory | Memory cells | CD19 antigen | Immunostimulation | Hematology | Immunomodulation | Research & development--R&D | Patients | Studies | Lymphocytes B | Response rates | Lymphomas | Histocompatibility antigen HLA | Tumors | Research & development | R&D
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6367 - 6382
Purpose: The study of the cancer secretome suggests that a fraction of the intracellular proteome could play unanticipated roles in the extracellular space... 
ONCOLOGY | PHOSPHORYLATION | MOBILITY GROUP A1 | RECEPTOR | PROLIFERATION | RAGE | HMGB1 | OPPORTUNITIES | PROTEINS | EXPRESSION | PROGRESSION
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2017, Volume 117, Issue 10, pp. 1478 - 1485
Journal Article
Palaeogeography, Palaeoclimatology, Palaeoecology, ISSN 0031-0182, 07/2017, Volume 477, pp. 10 - 26
The late Early Pleistocene site Barranc de la Boella provides an unparalleled opportunity to assess the context of the activities of the hominin populations... 
Lower Palaeolithic | Palaeoecology | El Forn | La Mina | Taphonomy | PERCUSSION MARKS | LIVING FLOOR | FLK 22 ZINJANTHROPUS | RESOURCE AVAILABILITY | GEOGRAPHY, PHYSICAL | GEOSCIENCES, MULTIDISCIPLINARY | PALEONTOLOGY | ARCHAEOFAUNAL ASSEMBLAGES | ELEPHANT-CARCASS | FUENTE NUEVA-3 ORCE | VENTA-MICENA ORCE | OLDUVAI-GORGE | CARNIVORE COMPETITION
Journal Article